Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Sermorelin and Ipamorelin — mechanism, dosing, side effects, legal status, and pricing.
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of GHRH. It was previously FDA-approved for diagnosing and treating pediatric GH deficiency and is now widely used in anti-aging medicine.
Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is considered one of the mildest GHRPs with fewer side effects than alternatives like GHRP-6.
Sermorelin
Ipamorelin
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
Side Effects
Contraindications
Previously FDA-approved (Geref) for pediatric GH deficiency before being discontinued for commercial reasons. Clinical data supports improved body composition, sleep quality, and skin elasticity in adults. It is one of the most well-characterized GH secretagogues.
Clinical studies have demonstrated its ability to increase GH release in a dose-dependent manner. It has been studied in post-surgical recovery and bone health contexts. It is frequently combined with CJC-1295 for synergistic GH elevation.
Sermorelin and Ipamorelin are both in the Performance category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Disclosed Labs